LDLRAP1 and ovarian carcinoma: Based on the results of our studies, it is expected that clinical trials will be conducted and validated with reference to the expression of clinical biomarkers such as VDAC1 and LDLRAP1, which can predict the response to statins in histological types other than mucinous carcinoma, for the purpose of add-on effects to standard paclitaxel–carboplatin therapy, maintenance therapy after initial treatment, or prevention of disease in high-risk patients with ovarian cancer.